Daiichi Sankyo gets Japenese nod for Tarlige tablets to treat neuropathic pain

Tokyo: Daiichi Sankyo Company, Limited has announced that the company has obtained approval in Japan to change the indication of the analgesic "Tarlige Tablets" (mirogabalin besilate) from "peripheral neuropathic pain" to "neuropathic pain."

Neuropathic pain is pain caused by lesions or diseases of the somatosensory nervous system and is classified into peripheral neuropathic pain and central neuropathic pain (CNP), according to the anatomical location of the nerve damage site that causes the pain. CNP is pain that arises from central nerve injury or impairment such as spinal cord injury and central post-stroke pain.

In May 2021, Daiichi Sankyo submitted a supplemental new drug application (sNDA) for Tarlige Tablets based on results from a phase 3 trial in patients with CNP.

"By delivering a new therapeutic option for CNP, Daiichi Sankyo hopes to contribute to healthcare of patients," the release stated.

Read also: Sun Pharma to acquire Daiichi's 11.28 percent stake in Zenotech